LncRNA H19 Drives Proliferation of Cardiac Fibroblasts and Collagen Production via Suppression of the miR-29a-3p/miR-29b-3p-VEGFA/TGF-β Axis

Feng Guo1, Chengchun Tang2*, Bo Huang1*, Lifei Gu1, Jun Zhou1, Zongyang Mo1, Chang Liu1, and Yuqing Liu3

1Department of Cardiology, Shanghai Electric Power Hospital, Shanghai 200050, China, 2Department of Cardiology, Zhongda Hospital Southeast University, Nanjing 210009, China, 3Department of Emergency, Naval Characteristic Medical Center Affiliated to Shanghai, Naval Medical University, Shanghai 200433, China
*Correspondence: devonchengchun@yeah.net (CT); xinneihuangbo@163.com (BH)
https://doi.org/10.14348/molcells.2021.0066
www.molcells.org

The aim of this study was to investigating whether lncRNA H19 promotes myocardial fibrosis by suppressing the miR-29a-3p/miR-29b-3p-VEGFA/TGF-β axis. Patients with atrial fibrillation (AF) and healthy volunteers were included in the study, and their biochemical parameters were collected. In addition, pcDNA3.1-H19, si-H19, and miR-29a/b-3p mimic/inhibitor were transfected into cardiac fibroblasts (CFs), and proliferation of CFs was detected by MTT assay. Expression of H19 and miR-29a/b-3p were detected using real-time quantitative polymerase chain reaction, and expression of α-smooth muscle actin (α-SMA), collagen I, collagen II, matrix metalloproteinase-2 (MMP-2), and elastin were measured by western blot analysis. The dual luciferase reporter gene assay was carried out to detect the sponging relationship between H19 and miR-29a/b-3p in CFs. Compared with healthy volunteers, the level of plasma H19 was significantly elevated in patients with AF, while miR-29a-3p and miR-29b-3p were markedly depressed (P < 0.05). Serum expression of lncRNA H19 was negatively correlated with the expression of miR-29a-3p and miR-29b-3p among patients with AF (r1 = -0.337, r2 = -0.236). Moreover, up-regulation of H19 expression and down-regulation of miR-29a/b-3p expression facilitated proliferation and synthesis of extracellular matrix (ECM)-related proteins. SB431542 and si-VEGFA are able to reverse the promotion of miR-29a/b-3p on proliferation of CFs and ECM-related protein synthesis. The findings of the present study suggest that H19 promoted CF proliferation and collagen synthesis by suppressing the miR-29a-3p/miR-29b-3p-VEGFA/TGF-β axis, and provide support for a potential new direction for the treatment of AF.

Keywords: atrial fibrillation, cardiac fibroblast proliferation, collagen synthesis, H19, miR-29a-3p, miR-29b-3p

INTRODUCTION

Atrial fibrillation (AF) is a common clinical arrhythmia that is characterized by decreased cardiac output, thromboembolism, stroke, and heart failure, all of which have a serious impact on human health. Global epidemiological data indicate there are currently around 33 million patients with AF, with an increase in prevalence of AF with increasing age (Rahman et al., 2014). Treatment options for AF are varied and
include medications and cardiac ablation, including atrioventricular node ablation and maze surgery. However, standard treatments currently available may not be wholly effective, resulting in either unresolved AF or recurrence (Bhatt and Fischer, 2015). Anatomical factors, ion channel and transport abnormalities and structural changes are associated with AF; however, the exact pathogenesis of AF, an important factor in guiding clinical treatment, has not yet been determined (Bhatt and Fischer, 2015).

Myocardial fibrosis (MF) is the most prominent type of structural remodeling in AF, and results in abnormal collagen fiber deposition in the extracellular matrix (ECM) of myocardial cells (Sheng et al., 2013). As MF processes, the proliferation of cardiac fibroblasts (CFs) increases, leading to an increase in the expression of type I collagen (Col I) and α-smooth muscle actin (α-SMA) (Tao et al., 2014c). It has been shown that long noncoding RNAs (lncRNAs) (Wang et al., 2015) and microRNAs (miRNAs) (Bauersachs, 2010) are involved in regulating the formation of MF, in addition to DNA methylation (Tao et al., 2014c) and histone deacetylation (Tao et al., 2014a). For example, lncRNA SENCR was found to be highly expressed in endothelial cells, vascular smooth muscle cells, and large artery tissues. Silencing SENCR might down-regulate expression of certain vascular smooth muscle contractile proteins (Uchida and Dommeller, 2015). Furthermore, lncRNA Mhrt, has been found extensively in myocardial tissue and tends to hinder cardiac hypertrophy and heart failure under normal circumstances. Under conditions of pathology, however, its transcription is inhibited by the activation of the Brg1-Hdac-Parp chromatin inhibition complex (Han et al., 2014). Of note, the competing endogenous RNA (ceRNA) theory suggests that lncRNAs and miRNAs are mutually regulated by competitively binding to corresponding mRNA response elements (MRES), thereby affecting post-transcriptional regulation of miRNAs (Karreth et al., 2011; Salmena et al., 2011; Tay et al., 2011). In the etiology of myocardial hypertrophy, lncRNA CHRF was found to reduce miR-489 expression by sponging it (Wang et al., 2014). Furthermore, lncRNA H19 promoted the multiplication of CFs via repression of DUSP5/ERK1/2 signaling (Tao et al., 2016); however, the sponge miRNAs that could be a factor in AF etiology have rarely been studied.

With the use of ENCORI online software (http://starbase.sysu.edu.cn/), we discovered that the miR-29 family, including miR-29a, miR-29b, and miR-29c, was sponged by lncRNA H19. Members of the miR-29 family were shown to target miRNAs of various ECM proteins, such as type I/III collagen and fibrillin, and to control fibrosis-related genes, such as laminin and integrin. Maurer et al. (2010) discovered that miR-29a expression in fibroblasts of patients with systemic sclerosis was significantly down-regulated compared to that in healthy individuals. Another study demonstrated that miR-29b showed low expression in patients with AF or congestive heart failure (Dawson et al., 2013). Taken together, lncRNA H19 could be implicated in the development of AF by exerting inhibitory effects on the miR-29 family. However, no existing evidence to date has been able to corroborate the importance of the lncRNA H19/miR-29a/b axis in CF function and AF development.

The aim of this investigation, therefore, was to determine if lncRNA H19 is involved in AF development by sponging the miR-29 family, and to elucidate a potential new area for AF treatment.

**MATERIALS AND METHODS**

**Clinical samples**

Ninety-eight patients with AF from the cardiology department at Zhongda Hospital Southeast University, and 75 healthy volunteers were recruited into the study. Patients with AF were included if they met the following criteria: 1) irregular R-R intervals, 2) absence of distinct repeating P waves, and 3) irregular atrial activity, which was identified with an electrocardiogram (EKG) by a cardiologist. Patients with AF were grouped by pathology into paroxysmal AF (AF lasting < 7 days), persistent AF (AF that persists for > 7 days), and permanent AF (AF that persists for > 12 months), according to the “2014 AHA/ACC/HRS Guidelines for the Management of Patients with Atrial Fibrillation” (January et al., 2014).

Patients with AF were excluded from the study if they had the following co-morbid disorders: malignant tumors, infectious diseases, connective tissue diseases, autoimmune diseases, Parkinson’s syndrome, Alzheimer’s disease, primary biliary cirrhosis, chronic bladder pain syndrome or severe renal diseases. In addition, patients with AF that occurred after surgery and during pregnancy, or was complicated by acute myocardial infarction, hyperthyroidism and hypertrophic cardiomyopathy, were also excluded. All research subjects volunteered for this study, and all participants signed informed consent forms prior to enrolment. The protocol for this study was approved by Zhongda Hospital Southeast University and the Ethics Committee of Zhongda Hospital Southeast University (No. 2019DKYSB057).

**Collection of blood samples from participants**

Upon admission, elbow venous blood was taken from each participant, who was instructed to fast for more than 12 h prior to the blood draw. An automatic biochemistry analyzer (Roche, Switzerland) was used to measure serum levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), creatinine (Cr), and high-sensitivity C-reactive protein (hs-CRP).

**Measurement of left atrial diameter and left ventricular ejection fraction (%)**

The left atrial diameter (LAD) and left ventricular ejection fraction (LVEF) were obtained by echocardiography performed with the Cardiovascular Ultrasound System (VIVID T8; GE Healthcare, USA).

**Cell culture**

Rat CFs (purchased from Shanghai iCell Bioscience, China), were incubated in 15% fetal bovine serum-containing DMEM, which included penicillin-streptomycin, and were placed in an atmosphere of 5% CO2 at 37°C. After the cells grew to 80% confluence, they were digested by 0.25% trypsin (Beyotime Institute of Biotechnology, China). The cells grew to 80% confluence, they were digested by 0.25% trypsin (Beyotime Institute of Biotechnology, China). The cells...
that were passaged for three generations were prepared for subsequent experiments.

**Cell treatment and transfection**

CFs of rats were transfected, respectively, by pcDNA3.1-lncRNA H19, si-lncRNA H19 (siRNA-1, F: 5'-TGACGGCGAGGACGGAGG-3'; R: 5'-CCCACAAGGAAGAAGAAGTT-3'; siRNA-2, F: 5'-GCCAAGGACGACACAGCTT-3'; R: 5'-AAAGCCAGUGGC-3'; siRNA-3, F: 5'-GCAUAGGACGCAAGAGATT-3'; R: 5'-AGCAGUGGCAAGUG-GC-3'), miR-29a-3p mimic (F: 5'-UAGCACCAUUGAAUUGGUUA-3'; R: 5′-ACCGAUUUGCAAGGCUAA-3′), miR-29a-3p inhibitor (F: 5′-UAACCGAUUUUGGUUAAGTT-3′; R: 5′-CAGUACUUUUGUGUAGUAA-3′), miR-29b-3p mimic (F: 5'-UAGCACCAUUGAAUUGGUUA-3'; R: 5'-AACACUGAUUUCAAAUGGUCA-3'), and miR-29b-3p inhibitor (5'-AACACUGAUUUCAAAUGGUCA-3'), according to the instructions of the Lipofectamine 2000 transfection reagent kit (Invitrogen, USA).

**Cell proliferation assay**

CFs seeded in 96-well plates were blended with a 5 mg/ml MTT solution (Beijing Solarbio Science & Technology, China), after which they were cultivated, respectively, for 0 h, 24 h, 48 h, and 72 h. After continuous incubation of CFs for 4 h, the cell supernatant was removed, and CFs from each well were mixed with 150 μl dimethyl sulfoxide (Amresco, USA) and shaken for 10 min. The optical density of the CFs was measured at 490 nm with a microplate reader (Bio-Tek, USA).

**Real-time quantitative polymerase chain reaction (RT-qPCR)**

Total RNA in CFs and blood samples was extracted by the addition of Trizol reagent (Beijing Tiangen Biotechnology, China). After synthesizing cDNAs according to the instructions of the reverse transcription kit (TaKaRa, Japan), the cDNAs were then amplified as instructed by a real-time fluorescent quantitative PCR kit (TaKaRa). Accordingly, 2^-△△CT method was employed to standardize gene expressions, with GAPDH and U6 as the internal reference.

**Western blot analysis**

The CFs were washed twice with pre-chilled phosphate-buffered saline (PBS), and subsequently lyed on ice in order to dissociate the proteins from the CFs. After determining the protein concentration using the BCA method, 40 μg of protein sample was removed in order to carry out electrophoresis, followed by transfer onto a PVDF membrane (Millipore, France). After blockage by 5% skimmed milk powder for 1 h, primary antibodies (rabbit anti-rat; Abcam, USA) against Bax (1:2,000, Cat. No. ab32503), Bcl-2 (1:1,000, Cat. No. ab32124), caspase-3 (1:5,000, Cat. No. ab32351), α-SMA (1:10,000, Cat. No. ab124964), collagen I (1:3,000, Cat. No. ab34710), collagen II (1:5,000, Cat. No. ab188570), MMP-2 (1:1,000, Cat. No. ab92536), elastin (1:1,000, Cat. No. ab213720), and GAPDH (1:2,500, Cat. No. ab9485) were added and the samples were incubated at 4°C overnight. After washing the membrane with PBST, a secondary antibody Goat Anti-Rabbit IgG H&L (HRP) (1:3,000, Cat. No. ab205718; Abcam) was added to incubate the resultants, and GAPDH was used as the control.

**Dual luciferase reporter gene assay**

CFs in the logarithmic growth phase was seeded in 24-well cell plates at a density of 5 × 10⁴/well. With the assistance of a dual luciferase reporter gene detection kit (lot No. E1913; Promega, USA), the pmirGLO-H19-Wt (Promega) and pmirGLO-H19-Mut were co-transfected, respectively, with miR-29a-3p/miR-29b-3p mimic, miR-29a-3p/miR-29b-3p inhibitor or miR-negative control (miR-NC) into CFs for 48 h. Relative luciferase activity, i.e., the ratio of reninase activity/luciferase

### Table 1. Comparison of baseline features between atrial fibrillation patients and healthy people

| Clinical characteristic | Atrial fibrillation group | Control group | χ²/t-test | P value |
|------------------------|--------------------------|---------------|-----------|---------|
| Sex                     |                          |               |           |         |
| Female                  | 48                       | 37            | 0.046     | 0.963   |
| Male                    | 50                       | 38            |           |         |
| Age (y)                 | 61.64 ± 7.05             | 60.12 ± 6.86  | 1.422     | 0.157   |
| Coronary heart disease  | 16 (16.3)                | 20 (26.7)     | 2.757     | 0.097   |
| Diabetes mellitus       | 8 (8.2)                  | 13 (17.3)     | 3.350     | 0.067   |
| Hypertension            | 27 (27.6)                | 25 (33.3)     | 0.676     | 0.411   |
| Smoking                 | 20 (20.4)                | 14 (18.7)     | 0.082     | 0.775   |
| LAD (mm)                | 44.89 ± 5.42             | 32.18 ± 4.26  | 16.73     | <0.001  |
| LVEF (%)                | 52.19 ± 6.13             | 63.75 ± 5.96  | 12.44     | <0.001  |
| TC (mmol/L)             | 4.06 ± 0.90              | 3.83 ± 1.21   | 1.434     | 0.153   |
| TG (mmol/L)             | 1.42 ± 0.42              | 1.30 ± 0.53   | 0.661     | 0.098   |
| LDL-C (mmol/L)          | 2.93 ± 0.49              | 2.27 ± 0.38   | 9.651     | <0.001  |
| HDL-C (mmol/L)          | 1.18 ± 0.41              | 1.10 ± 0.22   | 1.529     | 0.128   |
| hs-CRP (mg/L)           | 5.07 ± 3.02              | 1.16 ± 0.47   | 11.100    | <0.001  |
| Serum creatinine (μmol/L)| 68.58 ± 14.08             | 63.19 ± 12.61 | 2.609     | 0.010   |

Values are presented as number only, mean ± SD, or number (%).

LAD, left atrial diameter; LVEF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; CRP, C-reactive protein.
activity of CFs in each group was determined.

**Statistical analyses**

The data were statistically analyzed with SPSS 17.0 software (SPSS, USA). Numerical variables are expressed as mean ± SD, and were compared with the use of the Pearson chi-square test or one-way ANOVA. Statistical significance was defined as P < 0.05.

**RESULTS**

**Clinical traits of AF patients**

There were few, if any, significant differences between patients with AF and healthy individuals, with regards to gender, age, history of coronary heart disease, history of diabetes, history of hypertension, and smoking history (P > 0.05). However, LAD, LDL-C, and hs-CRP were significantly increased, and LVEF was significantly decreased in patients with AF, compared to that in healthy individuals (P < 0.05) (Table 1). Furthermore, LAD, LVEF, LDL-C, and hs-CRP increased with AF duration (P < 0.05) (Table 2).

In order to characterize the potential role of H19, miR-29a-3p, and miR-29b-3p in AF progression, their expression was measured by RT-qPCR. Serum levels of LncRNA H19 in AF patients increased to 1.60 times that of the control group, while siRNA-1, siRNA-2, and siRNA-3 inhibited H19 expression in CFs by 22%-53% of that in the control group (P < 0.05) (Fig. 3A). Among the siRNAs, siRNA-1 demonstrated the strongest degree of inhibition and was used for subsequent experiments. Furthermore, miR-29a-3p expression was promoted by an miR-29a-3p mimic, and suppressed under the influence of an miR-29b-3p inhibitor (P < 0.05) (Fig. 3B). Analogously, miR-29b-3p expression was up-regulated in the miR-29b-3p mimic group, and down-regulated in the miR-29b-3p inhibitor group, when compared with the NC group (P < 0.05) (Fig. 3C).

**LncRNA H19 sponged miR-29a-3p/miR-29b-3p to regulate CF activity and collagen production**

To explore the functional roles of LncRNA H19, miR-29a-3p, and miR-29b-3p in CF cell proliferation, apoptosis and collagen production, CF cells were transfected with either a control vector, pcDNA3.1-H19, si-H19, a mimic or an inhibitor. H19 expression in CFs of the pcDNA3.1-H19 group increased to 6.05 times that of the control group, while siRNA-1, siRNA-2, and siRNA-3 inhibited H19 expression in CFs by 22%-53% of that in the control group (P < 0.05) (Fig. 3A). Among the siRNAs, siRNA-1 demonstrated the strongest degree of inhibition and was used for subsequent experiments. Furthermore, miR-29a-3p expression was promoted by an miR-29a-3p mimic, and suppressed under the influence of an miR-29b-3p inhibitor (P < 0.05) (Fig. 3B). Analogously, miR-29b-3p expression was up-regulated in the miR-29b-3p mimic group, and down-regulated in the miR-29b-3p inhibitor group, when compared with the NC group (P < 0.05) (Fig. 3C).

**Table 2. Comparison of baseline features among patients with paroxysmal atrial fibrillation, persistent atrial fibrillation and permanent atrial fibrillation**

| Clinical characteristic | Paroxysmal atrial fibrillation group | Persistent atrial fibrillation group | Permanent atrial fibrillation | P value |
|-------------------------|--------------------------------------|--------------------------------------|-------------------------------|---------|
| Sex                     |                                      |                                      |                               |         |
| Female                  | 21                                   | 13                                   | 14                            | 0.037a  |
| Male                    | 15                                   | 20                                   | 15                            |         |
| Age (y)                 | 59.73 ± 6.43                         | 61.92 ± 6.97                         | 63.69 ± 7.48                  | 0.075   |
| Coronary heart disease  | 5                                    | 6                                    | 5                             | 0.879a  |
| Diabetes mellitus       | 3                                    | 3                                    | 2                             | 0.951a  |
| Hypertension            | 9                                    | 10                                   | 8                             | 0.886a  |
| Smoking                 | 6                                    | 8                                    | 6                             | 0.737a  |
| LAD (mm)                | 41.35 ± 4.27                         | 44.21 ± 3.67                         | 50.05 ± 4.38                  | -0.001b |
| LVEF (%)                | 55.46 ± 6.02                         | 52.24 ± 5.21                         | 48.07 ± 4.73                  | -0.001b |
| TC (mmol/L)             | 4.15 ± 0.74                          | 4.08 ± 0.91                          | 3.92 ± 1.07                   | 0.588b  |
| TG (mmol/L)             | 1.38 ± 0.40                          | 1.51 ± 0.48                          | 1.37 ± 0.35                   | 0.321b  |
| LDL-C (mmol/L)          | 2.68 ± 0.37                          | 2.94 ± 0.42                          | 3.22 ± 0.55                   | -0.001b |
| HDL-C (mmol/L)          | 1.19 ± 0.51                          | 1.22 ± 0.34                          | 1.12 ± 0.36                   | 0.630b  |
| hs-CRP (mg/L)           | 3.46 ± 1.62                          | 5.06 ± 2.27                          | 7.10 ± 3.84                   | -0.001b |
| Serum creatinine (μmol/L)| 64.71 ± 13.71                        | 69.64 ± 13.90                        | 72.19 ± 14.04                 | 0.089b  |

Values are presented as number only, mean ± SD, or number (%). The results are statistically significant when the P < 0.05. LAD, left atrial diameter; LVEF, left ventricular ejection fraction; TC, total cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; CRP, C-reactive protein.

*Pearson chi-square test. *One-way ANOVA.
Compared with the NC group, the viability and proliferation of CFs in the pcDNA3.1-H19 group and miR-29a-3p/miR-29b-3p inhibitor group was enhanced, whereas si-H19 and the miR-29a-3p/miR-29b-3p mimic reduced the viability and proliferative capability of CFs ($P < 0.05$) (Figs. 3D-3G). The results show that cell proliferation rate and colony formation ability in the pcDNA3.1-H19, miR-29a-3p/miR-29b-3p inhibitor group were significantly higher compared to that in the control group. On the contrary, apoptosis of CFs in the si-H19 group or in the miR-29a-3p/miR-29b-3p mimic group was significantly facilitated in comparison to the NC group; however, the apoptotic tendency of CFs in the pcDNA3.1-H19 group and miR-29a-3p/miR-29b-3p inhibitor was reversed, relative to that of the NC group ($P < 0.05$) (Figs. 4A and 4B). Similarly, the expression profile of apoptosis-related proteins was also changed. More specifically, pcDNA3.1-H19 and miR-29a-3p/miR-29b-3p inhibitors led to under-expression of Bax and cleaved caspase-3/total caspase-3, as well as over-expression of Bcl-2 ($P < 0.05$) (Figs. 4C and 4D). In contrast, transfection of si-H19 and miR-29a-3p/miR-29b-3p mimics increased expression of the Bax/caspase-3 ratio and decreased Bcl-2 expression ($P < 0.05$). Moreover, expression levels of $\alpha$-SMA, collagen I, collagen II, MMP-2, and elastin in the pcDNA3.1-H19 group and miR-29a-3p/miR-29b-3p inhibitor group were increased to 1.86-3.03 times of NC group, while expressions of $\alpha$-SMA, collagen I, collagen II, MMP-2, and elastin were significantly suppressed compared to the NC group ($P < 0.05$) (Fig. 5). The current results indicate that H19 overexpression and miR-29a-3p/miR-29b-3p under-expression significantly promote cell proliferation and collagen production, while inhibiting apoptosis in CF cells.

**Sponging relationship between lncRNA H19 and miR-29a-3p/miR-29b-3p**

Having determined the potential competitive mechanism between H19 and miR-29a-3p/miR-29b-3p, the present study attempted to identify critical direct targets underlying the mechanistic contribution of H19, miR-29a-3p, and miR-29b-3p to the progression of AF. The predicted binding site of miR-29a-3p/miR-29b-3p at the 3'-UTR of H19 site was determined using the starBase online database. The potential binding sequences are shown in Figs. 6A and 6C. A dual-luciferase reporter assay was conducted to validate direct
binding of the 3'-UTR of H19 mRNA with miR-29a-3p/miR-29b-3p. The luciferase activity of CFs in the pmiRGLO-H19-Wt+miR-29a-3p/miR-29b-3p mimic group was markedly restrained, when compared with the combined transfection of the pmiRGLO-H19-Mut-miR-29a-3p/miR-29b-3p mimic group and the pmiRGLO-H19-Wt-miR-NC group \(P < 0.05\) (Figs. 6A and 6C). Furthermore, miR-29a-3p/miR-29b-3p expression was significantly inhibited after transfection of pcDNA3.1-H19 \(P < 0.05\), and increased under the influence of si-H19 \(P < 0.05\) (Figs. 6B and 6D). In summary, the results from this study suggest that H19 regulate AF progression by binding to miR-29a-3p/miR-29b-3p.

**MiR-29a-3p mediated the effect of lncRNA H19 on CF activity and collagen production by targeting VEGFA and regulating TGF-β**

To further verify that miR-29a-3p regulates the activities of CF cells by targeting VEGFA and TGF-β, miR-29a-3p inhibitor alone or miR-29a-3p inhibitor combined with si-VEGFA or SB431542 was transfected into CF cells. The viability and multiplicative potential of CFs was enhanced, and CF apoptosis was slowed down in the miR-29a-3p inhibitor group comparison to the miR-29a-3p inhibitor+si-VEGFA group \(P < 0.05\) (Figs. 7A-7C). Moreover, CFs in the miR-29a-3p inhibitor+si-VEGFA group produced higher expressions of Bax and cleaved caspase-3/total caspase-3 ratio, relative to the miR-29a-3p inhibitor group \(P < 0.05\) (Supplementary Fig. S1D). Expressions of α-SMA, collagen I, collagen II, MMP-2 and elastin decreased in the miR-29a-3p inhibitor+SB431542 group compared to miR-29a-3p inhibitor group \(P < 0.05\) (Supplementary Fig. S1E).

The aforementioned results demonstrate that miR-29a-3p inhibitor promoted proliferation and collagen production, and inhibited apoptosis. This inhibition of apoptosis could be abolished with si-VEGFA/SB43152, suggesting that miR-29a-3p exerts its effects on cell proliferation, collagen production and cell apoptosis through VEGFA/TGF-β.

**MiR-29b-3p participated in the effect of lncRNA H19 on CF activity and collagen production by targeting TGF-β and modifying VEGFA**

To demonstrate the effect of miR-29b-3p on CF activities and collagen production through VEGFA and TGF-β, miR-29b-3p
inhibitor alone or combined with si-VEGFA or SB431542 was transfected into CF cells. CFs of miR-29b-3p inhibitor+TGF-β1 blocker (SB431542) group were associated with weaker viability and proliferative ability than CFs of the miR-29b-3p inhibitor group (P < 0.05) (Figs. 8A and 8B). Combined treatment of miR-29b-3p inhibitor and SB431542 contributed to a significant increase in the rate of apoptosis, which was 1.63 times of that in the miR-29b-3p inhibitor group (P < 0.05) (Fig. 8C). Joint treatment of miR-29b-3p inhibitor and SB431542 up-regulated expression of Bax and cleaved caspase-3 and down-regulated Bcl-2 expression, when compared with the miR-29b-3p inhibitor group (P < 0.05) (Fig. 8D). Moreover, SB431542 treatment (i.e., miR-29b-3p inhibitor+SB431542 group) reversed the contribution of miR-29b-3p inhibitor to collagen production, resulting in lower expressions of α-SMA, collagen I, collagen II, MMP-2, and elastin than miR-29b-3p inhibitor transfection alone (P < 0.05) (Supplementary Fig. S2E).

The above results showed that miR-29b-3p inhibitor promoted cell proliferation and collagen production, and inhibited apoptosis. These effects were reversed by si-VEGFA/SB431542. It was also shown that miR-29b-3p modified cell proliferation, collagen production and cell apoptosis through VEGFA/TGF-β.

**DISCUSSION**

AF is one of the most common subtypes of arrhythmia, occurring in 0.4% of the general population, with an incidence reaching high of 8% in elderly populations aged 80 years or
Fig. 4. Cell apoptosis were regulated by lncRNA H19, miR-29a-3p, and miR-29b-3p in CFs. (A and B) apoptosis were evaluated separately among negative control (NC), pcDNA3.1-H19, si-H19, miR-29a-3p mimic, and miR-29a-3p inhibitor group or NC, pcDNA3.1-H19, si-H19, miR-29b-3p mimic, and miR-29b-3p inhibitor group. *P < 0.05 when compared with NC. PI, propidium iodide; FITC, fluorescein isothiocyanate. (C and D) apoptins were determined between NC, pcDNA3.1-H19, si-H19, miR-29a-3p mimic, and miR-29a-3p inhibitor group and NC, pcDNA3.1-H19, si-H19, miR-29b-3p mimic, and miR-29b-3p inhibitor group. *P < 0.05 when compared with NC.

Fig. 5. ECM-related proteins of CFs were affected by lncRNA H19, miR-29a-3p, and miR-29b-3p. (A) ECM-related proteins were evaluated separately among negative control (NC), pcDNA3.1-H19, si-H19, miR-29a-3p mimic, and miR-29a-3p inhibitor group. *P < 0.05 when compared with NC. (B) ECM-related proteins were detected among negative NC, pcDNA3.1-H19, si-H19, miR-29b-3p mimic, and miR-29b-3p inhibitor group. *P < 0.05 when compared with NC.
LncRNA H19 Effect Atrial Fibrillation through miR-29a/b Axis
Feng Guo et al.

Fig. 6. Sponging relationships between H19 and miR-29a-3p/miR-29b-3p in CFs. (A) LncRNA H19 targeted miR-29a-3p, and luciferase activity of CFs was compared between pmiRGLO-H19-Wt+miR-29a-3p mimic group and pmiRGLO-H19-Wt+miR-NC group. NC, negative control. *P < 0.05 when compared with pmiRGLO-H19-Wt+miR-NC group. (B) MiR-29a-3p expression was determined after transfection of NC, pcDNA3.1-H19 and si-H19. *P < 0.05 when compared with NC. (C) MiR-29b-3p was targeted by lncRNA H19, and luciferase activity of CFs was compared between pmiRGLO-H19-Wt+miR-29b-3p mimic group and pmiRGLO-H19-Wt+miR-NC group. *P < 0.05 when compared with pmiRGLO-H19-Wt+miR-NC group. (D) MiR-29b-3p expression was measured after transfection of NC, pcDNA3.1-H19, and si-H19. *P < 0.05 when compared with NC.

Fig. 7. Cell activities were impacted by miR-29a-3p and si-VEGFA in CFs. Viability (A), proliferation (B), apoptosis (C), apoptins (D), and ECM-related proteins (E) of CFs were evaluated among miR-NC, miR-29a-3p inhibitor, and miR-29a-3p inhibitor+si-VEGFA group. NC, negative control; PI, propidium iodide; FITC, fluorescein isothiocyanate. *P < 0.05 when compared with miR-NC, #P < 0.05 when compared with miR-29a-3p inhibitor.
older (Fuster et al., 2001). AF typically leads to a reduction in heart function and the presence of arterial thromboembolism. The pathogenesis of AF is believed to relate to underlying factors including electrophysiological remodeling, structural remodeling, calcium homeostasis disorders, autonomic nervous system disorders, inflammation, and oxidative stress (Brundel et al., 2001; Dobrev and Nattel, 2008; Lee et al., 2006; Neef et al., 2010). Notably, the formation of atrial fibrosis promotes the remodeling of atrial structure and AF onset. To date, however, the pathogenesis of AF has yet to be elucidated.

After physicochemical or biological stimulation, MF excessively proliferated, resulting in an overexpression of SMA and a massive deposition of ECM proteins, such as type I/III/IV collagen (Hennemeier et al., 2014; Mir et al., 2012). In this investigation, we suggested that H19 was capable of promoting MF multiplication and collagen production (Figs. 3 and 4), which provided a molecular explanation for H19 as a clinical biomarker for AF progression (Fig. 1A). Abundant miRNAs in human cardiac tissue were observed, including miR-29a/b, miR-27a/b, miR-30a/b/c, and miR-92a/b (Dobrev and Nattel, 2008), and appeared to play a crucial role in regulating cardiovascular function, including miR-195 and miR-9 in cardiac hypertrophy (van Rooij et al., 2006; Wang et al., 2010), miR-320 in myocardial infarction (Ren et al., 2009) and miR-590 in cardiac fibrosis (Shan et al., 2009). According to a newly identified regulatory network, crosstalk between lncRNAs and miRNAs occurs during competition for shared miRNA response elements. Based on this observation, lncRNAs may function as ceRNAs to sponge miRNAs, thereby modulating the distribution of miRNA molecules on their targets and imposing an additional level of post-transcriptional regulation. Our study suggests that low expression of miR-29a and miR-29b, resulting from sponging and negative regulation of IncRNA H19 (Fig. 6), promotes collagen production and multiplication of CFs (Figs. 4 and 5). The significant correlation between IncRNA H19 expression and miR-29a/29b expression among patients with AF (Fig. 1B) also showed that miR-29a/29b expression was clinically modified due to changes in IncRNA H19 expression.

As formerly documented, low miR-29 expression predisposes the onset of CF, myocardial infarction, and aortic constriction by targeting and up-regulating ECM genes, including collagen, metalloproteinases, elastin, and fibrillin (Abonnenc et al., 2013; van Rooij et al., 2008). Moreover, miR-29a could alleviate MF progression by up-regulating expression of RASSF1A (Tao et al., 2014b), thereby inhibiting development of fibrosis (Ramdas et al., 2013). Thus, it was demonstrated that a variety of AF-causing genes were modified by miR-29. Here, we observed that VEGFA was sponged by miR-29a in CFs, resulting in the activation of CF proliferation and collagen release, which were inhibited by miR-29a (Fig. 7). In addition to CFs, VEGFA, an important mammalian growth factor (Koch et al., 2011), was also subjected to negative modulation of miR-29a in a human embryonic kidney cell line (i.e., HEK293) (Yang et al., 2013), suggesting that the miR-29a/VEGFA axis was shared by a variety of pathogenic mechanisms. Furthermore, impediment of VEGFA signaling clearly reduced the severity of liver fibrosis and slowed its increase (Yan et al., 2015). The HIF-1α-VEGF-ING-4 axis, the so-called angiogenesis axis, plays an important role in the pathogenesis of experimental pulmonary fibrosis and idiopathic pulmonary fibrosis (Smadja et al., 2014). Li et al. (2015) also found that the application of low molecular weight heparin reduced the expression of fibrosis-promoting factors in mice, such as VEGF, thereby attenuating the development of fibrosis. In summary, the miR-29a/VEGFA axis is vital for the role of IncRNA H19 in the development of AF. Furthermore, TGF-β...
is considered to be a pivotal downstream molecule of miR-29b in regulating AF etiology. TGF-β, a major target for the treatment of fibrotic lesions (Edgley et al., 2012), may induce proliferation of myocardial fibroblasts, secretion of collagen, and differentiation of myocardial fibroblasts into myofibroblasts (Guo et al., 2018). It has been reported that blocking TGF-β/Smad3 signaling could restore and alleviate myocardial dysfunction and MF caused by miRNA-29b knockdown (Zhang et al., 2014), which altogether suggests that TGF-β is pivotal in mediating the contribution of H19/miR-29b axis to AF progression.

In conclusion, lncRNA H19 contributes to the etiology of AF by dual regulation of the miR-29a/b-VEGFA/TGF-β axis, and this combination was an essential target in the development treatment strategies for AF. However, there were several shortcomings in the experimental design of this study. Firstly, patients with AF were not grouped according to severity of disease, so it was unclear whether the lncRNA H19-led miR-29a/b-VEGFA/TGF-β axis was altered to a different degree, with increasing severity of AF. Secondly, patients with AF who were included in the study were limited in terms of sample size and ethnicity. Therefore, it may not be appropriate to extrapolate the clinical conclusions from this study to populations of patients with AF. Thirdly, animal models of AF were not constructed to elucidate the role of the lncRNA H19-led miR-29a/b-VEGFA/TGF-β axis in AF progression. To increase the reliability of the underlying etiology of AF, additional, in-depth results from further studies will be needed.

Note: Supplementary information is available on the Molecules and Cells website (www.molcells.org).

ACKNOWLEDGMENTS
This work was financially supported by the National Natural Science Foundation of China (81970237).

AUTHOR CONTRIBUTIONS
F.G., C.T., B.H., L.G., J.Z., M.L., and Y.L. conceived and designed the experiments. F.G., C.T., B.H., L.G., J.Z., Z.M., C.L., and Y.L. performed the experiments. F.G., C.T., B.H., and L.G. analyzed the data. C.L. and Y.L. drafted the manuscript. All authors read and approved the final manuscript.

CONFLICT OF INTEREST
The authors have no potential conflicts of interest to disclose.

ORCID
Feng Guo https://orcid.org/0000-0001-9875-7375
Chengchun Tang https://orcid.org/0000-0003-1895-3849
Bo Huang https://orcid.org/0000-0002-9443-2992
Lifei Gu https://orcid.org/0000-0002-1797-2418
Jun Zhou https://orcid.org/0000-0001-9024-943X
Zongyang Mo https://orcid.org/0000-0002-3403-1222
Chang Liu https://orcid.org/0000-0002-1577-1081
Yuqing Liu https://orcid.org/0000-0002-3949-0137

REFERENCES
Abonnenc, M., Nabebaccus, A.A., Mayr, U., Barallobre-Barreiro, J., Dong, X., Cuello, F., Sur, S., Drozdov, I., Langley, S.R., Lu, R., et al. (2013). Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ. Res. 113, 1138-1147.
Bauersachs, J. (2010). Regulation of myocardial fibrosis by MicroRNAs. J. Cardiovasc. Pharmacol. 56, 454-459.
Bhatt, H.V. and Fischer, G.W. (2015). Atrial fibrillation: pathophysiologic and therapeutic options. J. Cardiovasc. Vas. Anesth. 29, 1333-1340.
Brundel, B.J., Van Gelder, I.C., Henning, R.H., Tieleman, R.G., Tuinenburg, A.E., Wietzes, M., Grandjean, J.G., Van Gilst, W.H., and Crijns, H.J. (2001). Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 103, 684-690.
Dawson, K., Wakis, R., Ordog, B., Claus, S., Chen, Y., Iwasaki, Y., Voigt, N., Qi, Y., Sinner, M.F., Dobb, D., et al. (2013). MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127, 1466-1475. 1475e1461-1428.
Dobbri, D. and Nattel, S. (2008). Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J. Cardiovasc. Pharmacol. 52, 293-299.
Edgley, A.J., Krum, H., and Kelly, D.J. (2012). Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc. Ther. 30, e30-e40.
Fuster, V., Ryden, LE, Asinger, R.W., Cannom, D.S., Crijns, H.J., Frye, R.L., Halperin, J.L., Kay, G.N., Klein, W.W., Levy, S., et al. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. 22, 1852-1923.
Guo, S., Meng, X.W., Yang, X.S., Liu, X.F., Ou-Yang, C.H., and Liu, C. (2018). Circumcision administration suppresses collagen synthesis in the hearts of rats with experimental diabetes. Acta Pharmacol. Sin. 39, 195-204.
Han, P., Li, W., Lin, C.H., Yang, J., Shang, C., Nuernberg, S.T., Jin, K.K., Xu, W., Lin, C.Y., Lin, C.J., et al. (2014). A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102-106.
Henemeyer, I., Humpf, H.U., Gekle, M., and Schwerdt, G. (2014). Role of microRNA-29b in the ocratoxin A-induced enhanced collagen formation in human kidney cells. Toxicology 324, 116-122.
January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C., Jr., Conti, J.B., Ellinor, P.T., Ezekowitz, M.D., Field, M.E., et al. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64, e1-e76.
Karreth, F.A., Tav, Y., Perna, D., Ala, T., Tari, S., Rust, A.G., DeNicola, G., Webster, K.A., Weiss, D., Perez-Mancera, P.A., et al. (2011). In vivo identification of tumor- suppressive PTEN cellRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147, 382-395.
Koch, S., Tugues, S., Li, X., Gualandi, L., and Claesson-Welsh, L. (2011). Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 437, 169-183.
Lee, K.W., Everett, T.H., 4th, Rahmutula, D., Guerra, J.M., Wilson, E., Ding, C., and Olgin, J.E. (2006). Pirfenidone prevents the development of a pulmonary fibrosis in a transgenic mouse model of idiopathic pulmonary fibrosis. J. Am. Coll. Cardiol. 48, 968-976.
Maurer, B., Stanczyk, J., Jungel, A., Akhtemisheva, A., Trenkmann, M., Brock, J. and Raw, A. (2013). Liver fibrosis and management of patients with hepatic diseases. Gastroenterology 145, 137-148.
M., Kowal-Bielecka, O., Gay, R.E., Michel, B.A., Distler, J.H., et al. (2010). MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62, 1733-1743.

Mir, S.A., Chatterjee, A., Mitra, A., Pathak, K., Mahata, S.K., and Sarkar, S. (2012). Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J. Biol. Chem. 287, 2666-2677.

Nattel, S., Burstein, B., and Doble, B. (2008). Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ. Arrhythm. Electrophysiol. 1, 62-73.

Neef, S., Dybkova, N., Sossalla, S., Ort, K.R., Fluschnik, N., Neumann, K., Seipel, R., Schondube, F.A., Hasenfuss, G., and Maier, L.S. (2010). CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocytes of patients with atrial fibrillation. Circ. Res. 106, 1134-1144.

Rahman, F., Kwan, G.F., and Benjamini, E.J. (2014). Global epidemiology of atrial fibrillation. Nat. Rev. Cardiol. 11, 639-654.

Ramdas, V., McBride, M., Denby, L., and Baker, A.H. (2013). Canonical transforming growth factor-beta signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29. Am. J. Pathol. 183, 1885-1896.

Ren, X.P., Wu, J., Wang, X., Sartor, M.A., Jones, K., Qian, J., Nicolaou, P., Pritchard, T.J., and Fan, G.C. (2009). MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119, 2357-2366.

Salmena, L., Poliseno, L., Tay, Y., Kats, L., and Pandolfi, P.P. (2011). A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 145, 353-358.

Shan, H., Zhang, Y., Lu, Y., Zhang, Y., Pan, Z., Cai, B., Wang, N., Li, X., Feng, T., Hong, Y., et al. (2009). Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc. Res. 83, 465-472.

Sheng, J., Shim, W., Wei, H., Lim, S.Y., Liew, R., Lim, T.S., Ong, B.H., Chua, Y.L., and Wong, P. (2013). Hydrogen sulphide suppresses human atrial fibroblast proliferation and transformation to myofibroblasts. J. Cell. Mol. Med. 17, 1345-1354.

Smadja, D.M., Nunes, H., Juvin, K., Bertil, S., Valeyre, D., Gaussem, P., and Israel-Biet, D. (2014). Increase in both angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis. Pathol. Biol. (Paris) 62, 391-394.

Tao, H., Cao, W., Yang, J.J., Shi, K.H., Zhou, X., Liu, L.P., and Li, J. (2016). Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis. Cardiovasc. Pathol. 25, 381-389.

Tao, H., Shi, K.H., Yang, J.J., Huang, C., Zhan, H.Y., and Li, J. (2014a). Histone deacetylases in cardiac fibrosis: current perspectives for therapy. Cell. Signal. 26, 521-527.

Tao, H., Yang, J.J., Chen, Z.W., Xu, S.S., Zhou, X., Zhan, H.Y., and Shi, K.H. (2014b). DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology 323, 42-50.

Tao, H., Yang, J.J., Shi, K.H., Deng, Z.Y., and Li, J. (2014c). DNA methylation in cardiac fibrosis: new advances and perspectives. Toxicology 323, 125-129.

Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S.M., Ala, U., Karreth, F., Poliseno, L., Provero, P., Di Cunto, F., et al. (2011). Coding-independent regulation of the tumor suppressor PTEN by competing endogenous miRNAs. Cell 147, 344-357.

Uchida, S. and Dimmelser, S. (2015). Long noncoding RNAs in cardiovascular diseases. Circ. Res. 116, 737-750.

van Rooij, E., Sutherland, L.B., Liu, N., Williams, A.H., McAnally, J., Gerard, R.D., Richardson, J.A., and Olson, E.N. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 103, 18255-18260.

van Rooij, E., Sutherland, L.B., Thatcher, J.E., DiMaio, J.M., Naseem, R.H., Marshall, W.S., Hill, J.A., and Olson, E.N. (2008). Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 105, 13027-13032.

Wang, K., Liu, F., Zhou, L.Y., Long, B., Yuan, S.M., Wang, Y., Liu, C.Y., Sun, T., Zhang, X.J., and Li, P.F. (2014). The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ. Res. 114, 1377-1388.

Wang, K., Long, B., Zhou, J., and Li, P.F. (2010). miR-9 and NFKB1 regulate myocardin hypertrophy. J. Biol. Chem. 285, 11903-11912.

Wang, X., Liu, T., Zhao, Z., and Li, G. (2015). Noncoding RNA in cardiac fibrosis. Int. J. Cardiol. 187, 365-368.

Yan, Z., Qu, K., Zhang, J., Huang, Q., Qu, P., Xu, X., Yuan, P., Huang, X., Shao, Y., Liu, C., et al. (2015). CD147 promotes liver fibrosis progression via VEGF-A/VEGFR2 signalling-mediated cross-talk between hepatocytes and sinusoidal endothelial cells. Clin. Sci. (Lond.) 129, 129-710.

Yang, L., Englandal, C.G., and Cheng, B. (2013). Social isolation impairs oral palatal wound healing in sprague-dawley rats: a role for miR-29 and miR-203 via VEGF suppression. PLoS One 8, e72359.

Zhang, Y., Huang, X.R., Wei, L.H., Chung, A.C., Yu, C.M., and Lan, H.Y. (2014). miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol. Ther. 22, 974-985.